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Abstract The antiproliferative ffects of TGF-/31 were investi- 
gated in a human breast adenocarcinoma cell line (MCF-7). We 
report that TGF-I~I inhibits proliferation through cell cycle ar- 
rest in G~. A MCF-7 cell subline (MCF-7(-)), in which the type 
II TGF-I~ receptor is not detected, was shown to be resistant o 
TGF-J~I growth inhibitory effect. Cdk2 kinase activity was inhib- 
ited in the MCF-7 sensitive cell subline in parallel with the inhibi- 
tion of cell cycle progression. In both sensitive and resistant cell 
lines, TGF-I~I treatment did not affect cdk2, cdk4, cyclin E and 
cyclin D1 mRNA and protein levels. However, in the MCF-7 
sensitive cell subline, a time-dependent increase in cells positive 
for p21 wArltclpl nuclear localization was observed after TGF-g31 
treatment. These findings suggest that TGF-131 inhibition of 
MCF-7 cell proliferation is achieved through a type II receptor- 
dependent down-regulation of Cdk2 kinase activity without mod- 
ification of Cdk and cyclin expression, but correlated with an 
increase in p21WAFvcmn uclear accumulation. 
Key words: TGF-Il; Cell cycle regulation; Cyclin-dependent 
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1. Introduction 
Transforming rowth factor-ill (TGF-Ill) inhibits epithelial 
cell proliferation by arresting the progression of the cell cycle 
at the Gl-to-S phase transition [1]. The molecular mechanisms 
of this growth inhibitory effect are still poorly understood and 
the signalling pathways used by TGF-Ill to arrest he cell cycle 
remain to be characterized. Three types of TGF-Il receptors 
(type I (50 kDa), II (80-100 kDa), and III (200-400 kDa)) have 
been identified using cross-linking experiments with radiola- 
belled TGF-Ill [2]. Type I and type II receptors have recently 
been cloned and shown to encode serine-threonine kinases [3,4]. 
Type II TGF-Il receptor is required for the antiproliferative 
activity of TGF-Ill, whereas the type I mediates the induction 
of several genes implicated in the interactions between cell and 
extracellular matrix [5,6]. Type III receptor (or betaglycan) is
not likely to mediate any of the TGF-Il biological activities but 
is a direct regulator of its access to the signalling receptors [7]. 
TGF-fll does not interfere with the binding of positive growth 
factors to their receptors or with their early signal transduction 
mechanisms. Previous work indicate that TGF-Il affects late 
events in the mitogenic pathways, such as c-myc expression [8] 
and phosphorylation f the retinoblastoma gene product (Rb). 
TGF-Ill retains Rb in a hypophosphorylated state that may 
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suppress progression i to the S phase [1]. Rb binds to D-type 
cyclins and is phosphorylated by cyclin-dependent kinases [9]. 
These 'Cdk' kinases are related to p34 ~°2, an essential regulator 
of entry into mitosis, and are thought to be involved, associated 
with GI cyclins, in the progression i GL [10] and the regulation 
of the Gl-to-S phase transition [11]. It has therefore been hy- 
pothesized that TGF-fll might regulate the expression or the 
activity of specific Cdk-cyclins complexes [12]. In mink lung 
epithelial cells, the growth inhibitory effect of TGF-Ill has been 
recently demonstrated to be linked to an inhibition of Cdk4 
synthesis [13], which appears to prevent he activation of the 
cyclin E-Cdk2 complex [14]. Recently, the existence of negative 
regulators of cyclin-Cdk complexes, the CKIs (cyclin-depend- 
ent kinase inhibitors) p16 INK4, p21 wnH/c~Pl and p27 KIP1, has 
been demonstrated [15]. It has been shown that in lung and 
mammary epithelial cells arrested in late G~ by TGF-Ill, the 
p27 Ktvl protein binds to cyclin E-Cdk2 complexes and prevents 
their activation [16,17]. A decrease in Cdk2 kinase activity 
induced by TGF-Ill was also accompanied by an induction of 
p21 wAH/cIPI in ovarian cancer cells [18]. Moreover, recent stud- 
ies demonstrate that an additional CKI, called p151NK4B, an 
inhibitor of Cdk4 and Cdk6 kinase activities, is strongly ex- 
pressed after TGF-Ill treatment of human keratinocytes [19]. 
These observations suggest that different CKIs may be impli- 
cated in TGF-ill-mediated cell cycle arrest. 
Here, we report a comparative study of TGF-Ill growth 
inhibitory effect on human breast adenocarcinoma sensitive 
(MCF-7) and resistant (MCF-7(-)) cell sublines. We have 
found that TGF-Ill arrests the cell cycle (i) in a type II TGF-fl 
receptor-dependent manner, (ii) with a decrease in Cdk2 kinase 
activity but in the absence of Cdk4 protein regulation, and 
(iii) with a 3 fold increase in the percentage of cells displaying 
a p21 wAFa/clP1 nuclear localization. 
2. Materials and methods 
2.1. Chemicals 
Porcine TGF-fll was purchased from R&D systems Inc. (Minneapo- 
lis, MN, USA). Propidium iodide and RNase A were obtained from 
Sigma. Bis(sulfosuccinimidyl) suberate (BS 3) was obtained from Pierce. 
[125I]TGF-fll (3000 Ci/mmol), [7-32p]ATP (3000 Ci/mmol) and 
[c~-32p]dCTP (3000 Ci/mmol) were obtained from NEN. 
2.2. Cell culture 
MCF-7 (passage 150) and MCF-7 (-) (passage 300) were grown in 
a humidified atmosphere (5% COz195% air) at 37°C in RPMI 1640 
medium supplemented with sodium hydrogen carbonate (2 g/l), 2 mM 
glutamine, 1 uM insulin, gentamycin (25 mg/1) and 5% fetal calf serum 
(FCS). CCL-64 cells were grown in MEM medium supplemented with 
sodium hydrogen carbonate (2 g/l), 2 mM glutamine, gentamycin (25 
mg/l) and 5% FCS. 
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2.3. Cell growth experiments 
Cells were plated in 35-mm Petri dishes at a density of 10,000 cells/ 
cm 2. On the following day, the media were changed and TGF-fll (40 
pM) was added. The media were changed every 3 days and cell number 
was determined. Cell cycle phase distribution was determined by ana- 
lytical DNA flow cytometry as previously described [20] using a 
Facscan flow cytometer (Becton Dickinson). 
2.4. TGF-fll receptor affinity labelling 
Subconfluent cells were affinity labelled using 80 pM [125I]TGF-fll 
in presence or absence of 4 nM unlabelled TGF-fll. TGF-,81 binding 
sites on intact monolayers were cross-linked to [JzsI]TGF-fll using BS 3 
according to [21]. Detergent extracts from affinity labelled cells were 
separated on 7% polyacrylamide gels under reducing conditions. For 
autoradiography, the dried gels were exposed to Hyperfilm MP (Amer- 
sham) at -70°C for 7 days. 
2.5. Northern blot 
Total cellular RNA was prepared using the one-step acid guanidin- 
ium isothiocyanate/phenol-chloroform extraction method [22], size 
fractionated (15 ,ug per lane) on 1.2% agarose-formaldehyde (2.2M) 
gels, blotted onto Hybond-N membrane (Amersham) by capillary 
transfer and UV cross-linked, mRNA expression was analysed using 
32p-labelled cDNA probes corresponding to the 1 kb BamHI BamHI 
human cdk2 fragment, he 1.3 kb EcoRV-BglII human cyclin D1 frag- 
ment, the 1.4 kb BamHI-HindIII human cyclin E fragment, and the 0.8 
kb EcoR~XhoI murine cdk4 fragment. In order to check for differences 
in the amounts of RNA transferred, the filters were probed with a 0.6 
kb 36B4 cDNA fragment [23]. Signal intensities were evaluated by 
scanning densitometry of the autoradiograms. 
2.6. Western blot, immunoprecipitation and kinase activity 
determination 
Cell lysates were obtained as described in [10]. Total proteins (70 pg) 
were analysed by electrophoresis on polyacrylamide gels (12%) and 
transferred to nitrocellulose membrane by semi-dry blotting. Western 
Blot experiments were performed using rabbit antibodies raised against 
human Cdk2 specific carboxy-terminal peptide [24], against purified 
human recombinant cyclin A [25] and cyclin D1 [10]. For Cdk4 and 
cyclin E, rabbit antibodies raised against specific carboxy-terminal pep- 
tides were prepared and characterized asdescribed in [10] for cyclin D1 
antibodies. Immunoprecipitations a d histone H1 kinase assays were 
performed as described in [24]. For p21 wAFl/ctpl detection by Western 
blot after Cdk2 immunoprecipitation, a monoclonal antibody against 
p21 wAFl/clp~ (Oncogene Science) was used at the dilution recommended 
by the manufacturer. 
2.7. Immunofluorescence 
Cells growing on glass coverslips were washed once with PBS and 
fixed in PBS/3.7% formaldehyde for 15 min at 4°C. Cell permeabiliza- 
tion was performed in PBS/0.25% Triton X-100 for 5 min at room 
temperature and methanol 100% for 10 min at -20°C. Cells were then 
washed twice in PBS and incubated in PBS/FCS 1% for 15 minutes at 
room temperature. Fixed and permeabilized cells were incubated over- 
night at 4°C with a monoclonal anti-p21 waw/clpl antibody (dilution 
1:100; Oncogene Science) in PBS/FCS 1%. After three washes in the 
same buffer, cells were incubated with Texas red-conjugated sheep 
anti-mouse antibody (dilution 1:200; Amersham). Coverslips were 
washed twice with PBS/FCS 1%, three times with PBS and finally 
incubated for 10 min at room temperature with a 0.1 pg/ml solution of 
DAPI in PBS. After an additional rinse in PBS, coverslips were 
mounted on glass slides with Mowiol. 
3. Results and discussion 
3.1. TGF-fll growth inhibitory effects 
Growth and cell cycle parameters were examined in human 
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Fig. (A) Time-course of TGF-fll growth inhibition effect on MCF-7 and MCF-7(-) cells untreated (open circles) or treated (filled circles) with TGF-fll 
(40 pM). Each point is the mean of triplicate determinations. (B) Time-course ffect of TGF-fll (40 pM) on cell cycle distribution in MCF-7 and 
MCF-7(-) cells. Circles, squares and triangles are for G~, S and G2 + M phases, respectively. Open symbols correspond to control cells; filled symbols 
correspond to TGF-fll (40 pM)-treated cells. Each point is the mean + S.D. of three independent experiments. 
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Fig. 2. Chemical cross-linking of ~2SI-labeled TGF-fll performed on CCL-64, MCF-7 and MCF-7(-) cells in the absence (lanes 1) or presence (lanes 
2) of a 50 fold excess of unlabeled TGF-fll. The position of molecular size markers are indicated. 
breast adenocarcinoma cell sublines (MCF-7 and MCF-7(-)) 
treated with TGF-fl l .  As shown in Fig. 1A, the addition of 
TGF-fl l (40 pM) to MCF-7 cells resulted in a time-dependent 
inhibition of cell proliferation. The half-maximal effect was 
observed with 5 pM TGF-fl l (data not shown). MCF-7(-)  cell 
proliferation was not affected by TGF-fll (Fig. 1A) even at 
concentrations a high as 100 pM (data not shown). A time- 
course study of the cell cycle distribution i MCF-7 cell sublines 
treated with TGF-fl l (40 pM) was performed using flow cytom- 
etry. MCF-7 cells showed little change until 24 hours of TGF- 
fll treatment, hen the percentage of cells in S phase began to 
fall while the percentage ofcells in G] phase increased (Fig. 1B). 
Under the same conditions, TGF-fl l did not affect he distribu- 
tion in the cell cycle phases of MCF-7(-)  cells. In the MCF-7 
cell line, TGF-fl l  inhibition of proliferation can be correlated 
with a specific arrest in the G] phase of the cell cycle. In the 
literature, there are conflicting reports concerning the sensitiv- 
ity of MCF-7 cells to TGF-fll [26,27]. These discrepancies 
might be due to the use of MCF-7 cell sublines cultivated at 
different passages, the cells diverging with time in culture. In 
our study, MCF-7(-)  cells were at passage 300 while MCF-7 
cells were at passage 150. 
3.2. MCF-7( - )  cells lack type II TGF-fl receptor 
By performing cross-linking experiments, we investigated 
whether the lack of TGF-fl l growth inhibitory effect on MCF- 
7(-) cells can be correlated with a modification of TGF-fl 
receptor expression (Fig. 2). CCL-64 cells were used as a posi- 
tive control since these cells are known to express three detect- 
able TGF-fl l binding proteins. The overall expression of TGF- 
fl receptors was lower in MCF-7 cell sublines compared to 
CCL-64 cells. In MCF-7 cells, a specific labelling with 
[~25I]TGF-fll was detectable above 200 kDa (type III receptor) 
and between 70 and 90 kDa, suggesting an overlap of type I and 
II TGF-fl receptors. In MCF-7(-) cells, no specific labelling 
could be observed at a position corresponding totype II TGF-fl 
receptor, whereas type I TGF-fl was detected as a single la- 
belled protein (70 kDa). Thus, the inability of TGF-fl l to block 
the cell cycle progression i  G] and to inhibit proliferation of 
MCF-7(-)  cells correlates with the fact that the type II TGF-/3 
receptor is undetectable in these cells. Furthermore, it has been 
previously reported that MCF-7 cells resistant to the TGF-fl 
growth inhibitory effect do not express mRNA for the type II 
TGF-/~ receptor [4]. Both type II and type I receptors are 
required for TGF-fl's biological effects [28]. However, the inac- 
tivation of type II receptor induces a specific abrogation of the 
TGF-fl l antiproliferative effect without affecting the TGF-fll 
effects on extracellular matrix [6]. We have shown that TGF-fll 
is able to induce its own transcription i MCF-7(-)  cells that 
are insensitive to its growth inhibitory effect [29], and to in- 
crease the expression of the jun gene family [30]. Hence, in 
MCF-7 cells, the modification of TGF-fl l sensitivity in long- 
term tissue culture specifically affects the growth inhibitory 
response in correlation with the loss of the type II TGF-fl 
receptor. 
3.3. Inhibition of Cdk2 kinase activity 
It has recently been reported that, in normal mink lung ep- 
ithelial cells, TGF-fl 1 inhibition of the Gl-tO-S phase transition 
was related to a lack of Cdk2-cyclin E complex activity [13,14]. 
We therefore investigated the regulation of this kinase activity 
in MCF-7 cell sublines during TGF-fl l treatment. In MCF-7 
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Fig. 3. Kinetic study of the TGF-fll effect on Cdk2 activity in MCF-7 
cells. Kinase activities were assayed on histone H1 after immunoprecip- 
itation with anti-Cdk2 antibodies on 750 ktg total proteins. Results are 
expressed as a percentage ofkinase activity in treated vs. untreated cells. 
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Fig. 4. Time~zourse effects of TGF-fll (40 pM) on cdk2, cdk4, cyclin D1 and cyclin E mRNA expression i MCF-7 and MCF-7(-) cells, mRNA 
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sensitive cells, the overall histone H1 kinase activity associated 
with immunoprecipitates of Cdk2 was found to decrease in 
parallel with the occurrence of cell cycle parameter modifica- 
tions (Fig. 3). In this cell line, cyclin A associated kinase activity 
was also decreased by 25% after 30 h of treatment. Since Cdk2 
is known to be predominantly in complex with cyclin A and to 
be involved in S phase progression [24], this result might in part 
reflect the inhibition of entry into S phase. In MCF-7(-) cells, 
neither the Cdk2 nor the cyclin A-associated kinase activities 
displayed any significant changes upon TGF-fll treatment 
(data not shown). 
3.4. Expression of cyclins and Cdks 
We investigated in the two MCF-7 cell sublines the TGF-fll 
effects on the expression of Cdks and cyclins implicated in 
Gl-tO-S phase progression. The relative levels of cdk4, cdk2, 
cyclin D1 and cyclin E mRNA were analysed by Northern 
blotting of total RNA from TGF-fll (40 pM) treated and un- 
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Fig. 5. Time-course effects of TGF-fl 1 (40 pM) on Cdk2, Cdk4, cyclin D I and cyclin E protein expression i  MCF-7 and MCF-7(-) cells. The identity 
and the significance ofthe upper band labelled with the anti-cyclin D1 antibody, present in several samples, isunder investigation. 
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treated MCF-7 and MCF-7(-) cells. As shown in Fig. 4, there 
was no detectable variation of these transcripts after TGF-fll 
treatment either in MCF-7 or in MCF-7(-) cells. In addition, 
Western blot analysis of cellular extracts did not reveal any 
modification of Cdk4, Cdk2, cyclin D1 and cyclin E protein 
levels induced by TGF-fll treatment inany of the two cell lines 
(Fig. 5). 
Several controversial observations have recently been re- 
ported about TGF-fll effects on the expression of cell cycle 
regulatory proteins. In human keratinocytes, TGF-fll de- 
creases Cdk4, Cdk2 and cyclin E at mRNA and protein levels 
[31]. In normal mink lung epithelial cells (CCL-64), a decrease 
in Cdk4 protein level in the absence of mRNA regulation was 
reported [13]. Moreover, in these cells, constitutive over-expres- 
sion of Cdk4 suppresses the agreement with those previously 
reported in CCL-64 cells by Koffet al. [14]. However, in MCF- 
7 cells sensitive to the TGF-fll antiproliferative effect, we did 
not detect any decrease in Cdk4 protein levels (Fig. 5), whereas 
TGF-fll reduced Cdk4 protein levels in normal endometrial 
cells (data not shown). The discrepancies in TGF-fll effects 
between ormal cells (CCL-64, keratinocytes and endometrial 
cells) and human mammary adenocarcinoma cells (MCF-7) 
may be cell specific and/or may reflect differences in cell cycle 
regulation between ormal and tumoral cells. 
3.5. Regulation of p21 WAFllClP1 in TGF-fll-treated MCF-7 cells 
An increase in p21 wAF1/¢IP~ has been recently reported in 
TGF-fll-treated ovarian adenocarcinoma cells [18]. We there- 
fore checked for the presence of p21 wAF1/clP1 in Cdk2 immuno- 
complexes from MCF-7 cells (Fig. 6A). We found that 
p21 wAvl/cIP1 was associated with Cdk2 both in control and 
TGF-fll-treated cells. However, due to the low level of 
p21 wAvl/ciP~ detected in Cdk2 immunoprecipitates, it was diffi- 
cult to conclude that TGF-fll induces a variation of 
p21 wAH/cIPI in these complexes. We therefore decided to inves- 
tigate by immunofluorescence wh ther p21 wAvl/clP1 subcellular 
localization was regulated (Fig. 6B and C). In 25% of control 
MCF-7 cells, p21 wAw/clP~ was detected in the nucleus. After 
TGF-fll treatment, we observed a time-dependent i crease in 
the number of p21 waw/c~Pt nuclear positive cells. 48 h after 
TGF-fll treatment, 62% of cells were positive. No such varia- 
tions were observed in TGF-fll-resistant MCF-7(-) cells under 
the same conditions. These results indicate that TGF-fll in- 
duces a nuclear accumulation f p21 wAvl/clPl in MCF-7 sensi- 
tive cells, p21 wAH/°el exists in association with active as well 
as inactive kinase complexes, and a very low variation in the 
level of inhibitor present in the complex could lead to an abrupt 
transition from a fully active to an essentially inactive kinase 
[19]. Thus, it is conceivable that an undetectable variation in the 
association of p21 wAH/clP1 with Cdk2 complexes could lead to 
inhibition of this kinase activity in MCF-7 cells. How the fine- 
tuning of this interaction is regulated by TGF-fll and what is 
WAFI/C1PI the significance ofnuclear localization of p21 are there- 
fore important questions that remain to be investigated. 
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